多発性硬化症：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Market Outlook 11
3.1 Global Markets 11
3.1.1 Forecast 11
3.1.2 Drivers and Barriers – Global Issues 13
4 Current and Future Players 17
4.1 Overview 17
4.2 Trends in Corporate Strategy 19
4.3 Company Profiles 21
4.3.1 Biogen Idec 21
4.3.2 Teva Pharmaceutical Industries 24
4.3.3 Merck Serono (EMD Serono) 27
4.3.4 Sanofi 30
4.3.5 Bayer HealthCare Pharmaceuticals 33
4.3.6 Novartis International 35
4.3.7 Hoffmann-La Roche 38
4.3.8 GlaxoSmithKline 40
5 Appendix 42
5.1 Bibliography 42
5.2 Abbreviations 42
5.3 Methodology 43
5.4 Forecasting Methodology 43
5.4.1 Diagnosed MS patients 43
5.4.2 Percent Drug-Treated Patients 44
5.4.3 Drugs Included in Each Therapeutic Class 44
5.4.4 Launch and Patent Expiry Dates 45
5.4.5 General Pricing Assumptions 46
5.4.6 Individual Drug Assumptions 47
5.4.7 Generic Erosion 50
5.4.8 Pricing of Pipeline agents 51
5.5 Physicians and Specialists Included in This Report 52
5.6 Primary Research – Prescriber Survey 53
5.7 About the Authors 53
5.7.1 Analysts 53
5.7.2 Global Head of Healthcare 54
5.8 About GlobalData 55
5.9 Contact Us 55
5.10 Disclaimer 55